Navigation Links
Whistleblower Lawyers Comment on New England Journal of Medicine Study
Date:5/12/2010

WASHINGTON, May 12 /PRNewswire/ -- The New England Journal of Medicine today released a study entitled, "Whistle-blower Experiences in Fraud Litigation Against Pharmaceutical Companies." Some of the whistleblower cases discussed in the report were brought by Phillips & Cohen LLP, a law firm with offices in Washington, DC, and San Francisco. Phillips & Cohen has specialized in representing whistleblowers for more than 20 years.

Comments from Erika Kelton, a Washington, DC, attorney with Phillips & Cohen LLP.  She has represented several whistleblowers in the pharma industry, including the pharma sales rep whose case against Pfizer Inc. for illegal marketing of Bextra settled last year for a record-breaking $1.8 billion, including a $1.3 criminal fine.

(See http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements531.asp.)

"The study confirms our experience with whistleblowers. Most complain internally about an illegal or unethical practice by their employer, assuming -- or hoping -- that their employer will change. Whistleblowers generally are loyal employees. Unfortunately employers often tend to repay that loyalty by retaliating against those who speak out.  People often turn to us after they have been fired or have raised their concerns with management but nothing changes.  Typically, whistleblowers decide to file a "qui tam" lawsuit as a last resort. Most are motivated more by exposing wrongdoing and stopping what often are harmful or dangerous practices than by any hope for a reward."

Comments from Eric Havian, a San Francisco attorney with Phillips & Cohen LLP. One of his whistleblower cases resulted in the largest settlement ever paid by a defense contractor in a whistleblower case. (See http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements514.asp)

"Financial incentives are important for whistleblowers. They encourage people who otherwise wouldn't do so to step forward. Rewards can be lifesavers for these people, many of whom have been fired from their jobs, blackballed in their industries and unable to find other work or only find work for which they are overqualified and underpaid.  There is no guarantee that someone who files a qui tam lawsuit will end up receiving a reward. But for those whistleblowers who persevere and are successful, the reward from a qui tam case can change their lives and compensate them for the personal and professional suffering they have endured."

About the False Claims Act

The False Claims Act, and similar state laws, allow private individuals to sue companies that are defrauding the government and recover funds on the government's behalf. Whistleblowers are entitled to 15 percent to 25 percent of the recovery that results from their "qui tam" lawsuits if the government joins their case and 30 percent if the government doesn't join.

About Phillips & Cohen LLP

Phillips & Cohen is the nation's most experienced and most successful law firm representing whistleblowers. The firm specializes in representing only whistleblowers and has done so for more than 20 years. "Qui tam" cases brought by Phillips & Cohen attorneys have resulted in $5.3 billion in recoveries for governments from civil settlements and related criminal fines. Nearly 70 of Phillips & Cohen's clients have had successful qui tam cases, collecting more than $500 million in rewards – a record unmatched by any other law firm. For more info, see www.phillipsandcohen.com.


'/>"/>
SOURCE Phillips & Cohen LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax
2. Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States
3. Pfizer Whistleblower Named Years Most Influential Person In Business Ethics
4. Whistleblowers Attorney Says Pfizers Guilty Plea Today Opens New Chapter on Aggressive Enforcement of Pharma Companies
5. AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma
6. URAC Pharmacy Accreditation Programs Now Open For Public Comment
7. Relators Attorneys Comment On AtriCure/DOJ Proposed Settlement
8. Endologix Comments on Alleged Patent Infringement
9. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
10. ACRO Comments on NEJM Article on Globalization of Clinical Research
11. Arpida Comments on FDAs Anti-infective Drugs Advisory Committee Outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
Breaking Medicine News(10 mins):